Media library

Access photos, images, or videos for stories in development. If you are a member of the working press and need a resource that is not available on this website, please email your request to media@bms.com and we will make every effort to respond as soon as possible. Please read our terms for usage.

Key facts

updated June 2023

Chief Executive Officer:
Headquarters:
Princeton, New Jersey
Business:
Biopharmaceuticals
Web Address:
NYSE Listing:
BMY
Total Revenues:
$46.2 billion in 2022
R&D Investment:
$9.5 billion in 2022, which included the discovery and development of new medicines for patients
2022 Worldwide Revenues:

ELIQUIS® (apixaban), $11.8 billion

REVLIMID® (lenalidomide), $10.0 billion

OPDIVO®(nivolumab), $8.2 billion

POMALYST® / Imnovid® (pomalidomide), $3.5 billion

ORENCIA® (abatacept), $3.5 billion

SPRYCEL® (dasatinib), $2.2 billion

YERVOY® (ipilimumab), $2.1 billion

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), $811 million

REBLOZYL® (luspatercept-aamt), $717 million

ABECMA® (idecabtagene vicleucel), $388 million

EMPLICITI® (elotuzumab), $296 million

OPDUALAG(nivolumab and relatlimab-rmbw): $252 million

ZEPOSIA® (ozanimod), $250 million

BREYANZI® (lisocabtagene maraleucel), $182 million

ONUREG® (azacitidine tablets), $124 million

INREBIC® (fedratinib), $85 million

CAMZYOS® (mavacamten), $24 million

SOTYKTU(deucravacitinib), $8 million

Mature and other products* $1.8 billion 

*Includes products that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue.

Please click on the product links to see the Full Prescribing Information for ABECMA®ABRAXANE® , BREYANZI® CAMZYOS® ELIQUIS®, EMPLICITI®, INREBIC®, ONUREG® OPDIVO®, OPDUALAG, ORENCIA®, POMALYST® , REBLOZYL®REVLIMID® SOTYKTU SPRYCEL® , YERVOY®  and  ZEPOSIA® including Boxed WARNINGS for ABECMA®ABRAXANE®BREYANZI® CAMZYOS® ELIQUIS®INREBIC®, POMALYST®, REVLIMID®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.

Bristol Myers Squibb Corporate B-roll

Overview B-roll

This B-roll includes a collection of footage of Bristol Myers Squibb campus exteriors, corporate signage, research and development, and manufacturing facilities.


Usage Rights & Restrictions: These media assets are free for editorial broadcast, print, online and radio use. They are restricted for other purposes.

Building Signage
Scientific Media Resources
Disease State Infographics